Диссертация (1140142), страница 20
Текст из файла (страница 20)
Mlynarek R.A., Kuhn A.W., Bedi A. Platelet-Rich Plasma (PRP) inOrthopedic Sports Medicine // Am. J. Orthop. (Belle Mead NJ). ‒ 2016. ‒ Vol. 45,№ 5. ‒ P. 290-326.229. Mohammad T.F., Hamzavi I.H. Surgical Therapies for Vitiligo //Dermatol. Clin. ‒ 2017. ‒ Vol. 35, № 2. ‒ P. 193-203.230. Mohanty S., Kumar A., Dhawan J. et al. Noncultured extracted hairfollicle outer root sheath cell suspension for transplantation in vitiligo // Br. J.Dermatol. ‒ 2011. ‒ Vol. 164, № 6. ‒ P. 1241-6.231.
Moneib H.A., Youssef S.S., Aly D.G. et al. Autologous platelet-richplasma versus conventional therapy for the treatment of chronic venous leg ulcers:A comparative study // J. Cosmet. Dermatol. ‒ Epub 2017 Aug 19.232. Mosenson J.A., Eby J.M., Hernandez C., Le Poole I.C. A central rolefor inducible heat-shock protein 70 in autoimmune vitiligo // Exp Dermatol. ‒2013. ‒ Vol.
22, № 9. ‒ P. 566-569.233. Mosenson J.A., Zloza A., Nieland J.D. et al. Mutant HSP70 reversesautoimmune depigmentation in vitiligo // Sci. Transl. Med. ‒ 2013. ‒ Vol. 5, №174. ‒ P. 174.234. Mulekar S.V. Melanocyte-keratinocyte cell transplantation for stablevitiligo // Int. J. Dermatol. ‒ 2003. ‒ Vol. 42, № 2. ‒ P. 132-136.235. Mulekar S.V., Isedeh P. Surgical interventions for vitiligo: anevidence-based review // Br.
J. Dermatol. ‒ 2013. ‒ Vol. 169 Suppl 3. ‒ P. 57-66.236. Nantel-Battista M., Richer V., Marcil I., Benohanian A. Treatment ofnail psoriasis with intralesional triamcinolone acetonide using a needle-free jetinjector: a prospective trial // J. Cutan. Med. Surg. ‒ 2014. ‒ Vol.18, №1. ‒ P. 3842.124237. Nasti T.H., Timares L.
Inflammasome activation of IL-1 familymediators in response to cutaneous photodamage // Photochem. Photobiol. - 2012.- Vol.88(5). - P.1111-1125.238. Nguyen T.V., Cowen E.W., Leslie K.S. Autoinflammation: Frommonogenic syndromes to common skin diseases// J. Am. Acad. Dermatol. - 2013.- Vol.68(5). - P.834-853.239. Nicolaidou E., Antoniou C., Stratigos A.J.
et al. Efficacy, predictors ofresponse, and long-term follow-up in patients with vitiligo treated with narrowbandUVB phototherapy // J Am Acad Dermatol. ‒ 2007. ‒ Vol. 56, № 2. ‒ P. 274-278.240. Nicolaidou E., Antoniou C., Stratigos A., Katsambas A.D.Narrowband ultraviolet B phototherapy and 308-nm excimer laser in the treatmentof vitiligo: a review // J. Am.
Acad Dermatol. - 2009. - Vol.60. - P.470-477.241. Njoo M.D., Bos J.D., Westerhof W. Treatment of generalized vitiligoin children with narrow-band (TL-01) UVB radiation therapy // J. Am. Acad.Dermatol. ‒ 2000. ‒ Vol. 42, № 2 Pt 1. ‒ P. 245-253.242. Njoo M.D., Spuls P.I., Bos J.D. et al. Nonsurgical repigmentationtherapies in vitiligo. Meta-analysis of the literature // Arch.
Dermatol. ‒ 1998. ‒Vol. 134, № 12. ‒ P. 1532-1540.243. Nouri-Koupaee A., Mansouri P., Jahanbini H. et al. Differentialexpression244. of mRNA for T-bet and GATA-3 transcription factors in peripheralblood mononuclear cells of patients with vitiligo // Clin. Exp. Dermatol. - 2015;2015. - Vol.40(7). - P.735-740.245. Novak Z., Bonis B., Baltas E. et al. Xenon chloride ultraviolet B laseris more effective in treating psoriasis and in inducing T cell apoptosis than narrowband ultraviolet B // J.
Photochem. Photobiol. B. ‒ 2002. ‒ Vol. 67, № 1. ‒ P. 3238.246. Oliveira Filho M.A., Nassif P.A., Malafaia O. et al. Effects of a highlyconcentrated platelet-rich plasma on the bone repair using non-critical defects inthe calvaria of rabbits // Acta Cir. Bras. ‒ 2010. ‒ Vol. 25, № 1. ‒ P. 28-33.125247.
Oliver E., Schwartz L., Warren L. Occupational leukodermapreliminary report // JAMA. ‒ 1939. № 113. ‒ P. 927-928.248. Onunu A.N., Kubeyinje E.P. Vitiligo in the Nigerian African: a studyof 351 patients in Benin City, Nigeria // Int. J. Dermatol. ‒ 2003. ‒ Vol. 42, № 10.‒ P. 800-802.249. Ortonne J. Vitiligo and other disorders of hypopigmentation / In: J.Jorizzo, R. Rapini, eds. Dermatology Bolognia, Vol. 1, 2nd edn. - Spain: Elsevier,2008. - 65 p.250. Ozawa M., Ferenczi K., Kikuchi T. et al.
312-nanometer ultraviolet Blight (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions // J.Exp. Med. ‒ 1999. ‒ Vol. 189, № 4. ‒ P. 711-718.251. PacificoA.,LeoneG.Photo(chemo)therapy forvitiligo//Photodermatol. Photoimmunol. Photomed. ‒ 2011. ‒ Vol. 27, № 5. ‒ P. 261-277.252. Parambath N., Sharma VK., Parihar A.S. et al. Use of platelet-richplasma to suspend noncultured epidermal cell suspension improves repigmentationafter autologous transplantation in stable vitiligo: a double-blind randomizedcontrolled trial // Int J Dermatol.
- 2019. - Vol.58(4). - P.472-476.253. Paul W.E., Zhu J. How are T(H)2-type immune responses initiatedand amplified? // Nat. Rev. Immunol. - 2010. - Vol.10(4). -P.225-235.254. Picard F., Hersant B., Niddam J., Meningaud J.P. Injections ofplatelet-rich plasma for androgenic alopecia: A systematic review // J. Stomatol.Oral Maxillofac.
Surg. ‒ 2017. – Epub 2017 Aug 1.255. Ponsonby A.L., Lucas R.M., van der Mei I.A. UVR, vitamin D andthree autoimmune diseases--multiple sclerosis, type 1 diabetes, rheumatoid arthritis// Photochem. Photobiol. ‒ 2005. ‒ Vol. 81, № 6. ‒ P. 1267-1275.256. Radakovic-Fijan S., Furnsinn-Friedl A.M., Honigsmann H., Tanew A.Oral dexamethasone pulse treatment for vitiligo // J.
Am. Acad. Dermatol. ‒ 2001.‒ Vol. 44, № 5. ‒ P. 814-817.257. Radakovic S., Breier-Maly J., Konschitzky R. et al. Response ofvitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective,126randomized, observer-blinded trial // J. Eur. Acad. Dermatol. Venereol. ‒ 2009. ‒Vol. 23, № 8. ‒ P. 951-953.258. Rashighi M., Agarwal P., Richmond J.M. et al. CXCL10 is critical forthe progression and maintenance of depigmentation in a mouse model of vitiligo //Sci. Transl. Med.
‒ 2014. ‒ Vol. 6, № 223. ‒ P. 223259. Redaelli A., Romano D., Marciano A. Face and neck revitalizationwith platelet-rich plasma (PRP): clinical outcome in a series of 23 consecutivelytreated patients // J. Drugs Dermatol. - 2010. - Vol. 9. - P. 466–472.260. Regazzetti C., Joly F., Marty C. et al. Transcriptional Analysis ofVitiligo Skin Reveals the Alteration of WNT Pathway: A Promising Target forRepigmenting Vitiligo Patients // J. Invest.
Dermatol. ‒ 2015. ‒ Vol. 135, № 12. ‒P. 3105-3114.261. Reimann E., Kingo K., Karelson M. et al. The mRNA expressionprofile of cytokines connected to the regulation of melanocyte functioning invitiligo skin biopsy samples and peripheral blood mononuclear cells // Hum.Immunol. - 2012. - Vol.73(4). - P.393-398.262. Reimann E., Kingo K., Karelson M. et al. Expression profile of genesassociated with the dopamine pathway in vitiligo skin biopsies and blood sera //Dermatology. - 2012. - Vol.224 (2). - P.168-176.263. Reimann E., Kingo K., Karelson M.
et al. Analysis of the expressionprofile of CRH-POMC system genes in vitiligo skin biopsies // J. Dermatol. Sci. 2010. - Vol.60(2). - P.125-128.264. Richmond J.M., Frisoli M.L., Harris J.E. Innate immune mechanismsin vitiligo: danger from within // Curr. Opin.
Immunol. ‒ 2013. ‒ Vol. 25, № 6. ‒P. 676-682.265. Rork J.F., Rashighi M., Harris J.E. Understanding autoimmunity ofvitiligo and alopecia areata // Curr. Opin. Pediatr. ‒ 2016. ‒ Vol. 28, № 4. ‒ P. 463469.266. Roychoudhuri R., Hirahara K., Mousavi K. et al.
BACH2 represseseffector programs to stabilize T(reg)mediated immune homeostasis // Nature. -1272013. - Vol.498 (7455). - P.506-510.267. Sanchez A.R., Sheridan P.J., Kupp L.I. Is platelet-rich plasma theperfect enhancement factor? A current review // Int J Oral Maxillofac Implants. ‒2003. ‒ Vol. 18, № 1. ‒ P. 93-103.268.
Sanclemente G., Garcia J.J., Zuleta J.J. et al. A double-blind,randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxidein vitiligo // J. Eur. Acad. Dermatol. Venereol. ‒ 2008. ‒ Vol. 22, № 11. ‒ P. 13591364.269. Sapam R., Agrawal S., Dhali T.K. Systemic PUVA vs. narrowbandUVB in the treatment of vitiligo: a randomized controlled study // Int J Dermatol. ‒2012. ‒ Vol. 51, № 9. ‒ P. 1107-1115.270. Sardana K., Verma G.
Overview of Medical Therapies andPhototherapy in Vitiligo Based on Their Pathogenetic Action and the Role ofPlatelet-Rich Plasma // J Cutan Aesthet Surg. - 2018. - Vol.11(4). - P.167-168.271. Sardi J.R. Surgical treatment for vitiligo through hair follicle grafting:how to make it easy // Dermatol. Surg. ‒ 2001.
‒ Vol. 27, № 7. ‒ P. 685-686.272. Shah A.N., Marfatia R.K., Saikia S.S. A Study of NonculturedExtracted Hair Follicle Outer Root Sheath Cell Suspension for Transplantation inVitiligo // Int. J. Trichology. ‒ 2016. ‒ Vol. 8, № 2. ‒ P. 67-72.273. Shajil E.M., Marfatia Y.S., Begum R. Acetylcholine esterase levels indifferent clinical types of vitiligo in Baroda, Gujarat // Indian J.
Dermatol. - 2006.Vol.51.- P.289-291.274. Sharma S., Garg V.K., Sarkar R., Relhan V. Comparative study offlip-top transplantation and punch grafting in stable vitiligo // Dermatol. Surg. ‒2013. ‒ Vol. 39, № 9. ‒ P. 1376-1384.275. Shen C., Gao J., Sheng Y. et al.
Genetic Susceptibility to Vitiligo:GWAS Approaches for Identifying Vitiligo Susceptibility Genes and Loci // Front.Genet. ‒ 2016. ‒ Vol. 7. ‒ P. 3.276. Shenoi S.D., Srinivas C.R., Pai S. Treatment of stable vitiligo withautologous epidermal grafting and PUVA // J. Am. Acad. Dermatol. ‒ 1997. ‒ Vol.12836, № 5 Pt 1. ‒ P. 802-803.277. Shih S. Platelet-rich plasma: Potential role in combined therapy forvitiligo // Dermatol Ther. - 2019. - Vol.32(1):e12773.278.
Singh C., Parsad D., Kanwar A.J. et al. Comparison betweenautologous noncultured extracted hair follicle outer root sheath cell suspension andautologous noncultured epidermal cell suspension in the treatment of stablevitiligo: a randomized study // Br. J. Dermatol. ‒ 2013. ‒ Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
